MHRAapproval72% confidence
Access, new active substance and biosimilar work sharing initiatives
Source: MHRA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to AbbVie.
Regulatory Analysis
Information on applying for New Active Substance Work Sharing Initiative (NASWSI) and Biosimilar Work Sharing Initiative (BSWSI) assessments and list of approved products.
Supporting Context
- Therapeutic area
- Immunology · Biosimilar
- Sub-indication
- General
Related signal: FDA Accepts Supplement Application for HADLIMA (Adalimumab Biosimilar)